Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical University of South Carolina
With
Gilead Sciences
Primary Endpoint: Change in 6 minute walk distance.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Biopsy proven sarcoidosis
Mean pulmonary artery pressure \> 25 mmHg at rest and greater than 30 mmHg with exercise by right heart catheterization within 1 year prior to entry into study
Pulmonary capillary wedge pressure ≤ 15 mmHg
PVR values \>3.0 Woods units
Forced vital capacity (FVC) \>40%
WHO functional class II or III
Stable sarcoidosis treatment regimen for three months prior to entry into study
6 minute walk distance between 150-450 meters
Stable dose of antihypertensive medications
On no other medication to treat PAH (sildenafil, tadalafil, vardenafil, treprostinil, epoprostenol, iloprost, bosentan, sitaxsentan) within one month prior to enrollment and during duration of the study
Non-pregnant females
You may not be if
Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)
Severe systemic hypertension \> 170/95
Patients with congestive heart failure (left ventricular dysfunction) or primary right ventricular dysfunction
Anticipation by the investigator for escalation in sarcoidosis treatment during the course of the study
Pulmonary hypertension related to etiology other than sarcoidosis (i.e. HIV, scleroderma, etc.)
Use within 1 month of an endothelin receptor antagonists (bosentan, sitaxsentan).
WHO functional class IV status
Patients with significant left ventricular dysfunction
Significant liver dysfunction not due to sarcoidosis.
Patients with severe other organ disease felt by investigators to impact on survival during the course of the study.
